{"product_id":"aytubio-marketing-mix","title":"Aytu Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Aytu’s product lineup, pricing architecture, distribution channels, and promotional tactics combine to create market impact—this concise preview hints at strategic strengths and opportunities.\u003c\/p\u003e\n\u003cp\u003eUnlock the full 4P’s Marketing Mix Analysis for an editable, presentation-ready report with real-world data, actionable insights, and templates to save hours of work and power client presentations or coursework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized ADHD Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu BioPharma’s Specialized ADHD Portfolio centers on Adzenys XR-ODT and Cotempla XR-ODT, proprietary orally disintegrating tablet and liquid formulations that address swallowing challenges and drive patient adherence.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 these ADHD products remained core revenue drivers, contributing roughly 45% of ADHD segment sales and supporting Aytu’s reported FY2024 net product revenue of about $78M; their extended-release design delivers consistent daytime symptom control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanded Ophthalmology Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing the strategic merger with Alimera Sciences, Aytu integrated high-value ophthalmic implants Iluvien and Yutiq, targeting diabetic macular edema and non-infectious uveitis with sustained-release intravitreal delivery.\u003c\/p\u003e\n\u003cp\u003eThis move diversified Aytu from primary care into high-margin specialty medicine; by Q4 2025 ophthalmology sales drove roughly 35% of revenue and materially reweighted the company’s therapeutic focus.\u003c\/p\u003e\n\u003cp\u003eAnalysts in 2025 attributed about 30–40% of Aytu’s enterprise value to the ophthalmology portfolio, reflecting higher gross margins and recurring implant-driven revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric and Primary Care Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu’s Pediatric and Primary Care line, including Karbinal ER and multiple pediatric multivitamins, targets allergy control and nutritional gaps; liquid and chewable forms drive differentiation and a higher adherence rate. In 2025 the segment contributed roughly 18% of Aytu BioPharma’s net revenue (about $6.5M of $36M year-to-date), supplying recurring prescriptions and steady gross margins near 60%. This steady stream deepens clinic ties and stabilizes cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Pipeline Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAytu’s product strategy centers on late-stage pipeline candidates, notably AR101 for Ehlers-Danlos Syndrome, advanced through 2025 to target rare-disease unmet needs and boost long-term revenue potential.\u003c\/p\u003e\n\u003cp\u003eThese assets, backed by orphan drug designations, aim to shorten approval timelines and raise institutional interest; pipeline progress is key to valuation and partnership deals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAR101: late-stage, Ehlers-Danlos focus, orphan designation\u003c\/li\u003e\n\u003cli\u003eTargeted rare-disease market; high price per patient models\u003c\/li\u003e\n\u003cli\u003ePipeline drives long-term growth and institutional funding\u003c\/li\u003e\n\u003cli\u003eOrphan status used to accelerate commercialization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Delivery Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA central product strength is Aytu’s LiquiXR and ODT delivery platforms, which convert immediate‑release molecules into extended‑release, easier‑to‑swallow formats, differentiating Aytu from generic rivals.\u003c\/p\u003e\n\u003cp\u003eThese platforms target ADHD and pediatric niches, raising technical barriers to entry; by late 2025 Aytu is actively seeking licensing deals to monetize IP, with potential royalty upside versus standalone product sales.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick facts:\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLiquiXR\/ODT: extended‑release conversion tech\u003c\/li\u003e\n\u003cli\u003eTargets ADHD\/pediatric markets—higher compliance\u003c\/li\u003e\n\u003cli\u003eLicensing push by late 2025 to unlock IP value\u003c\/li\u003e\n\u003cli\u003eCreates competitor barrier in specialized segments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAytu: ADHD \u0026amp; eye implants fuel 80% of revenue; AR101 offers orphan upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu’s product mix centers on ADHD ODT\/LiquiXR leaders (Adzenys, Cotempla) driving ~45% of ADHD sales and supporting FY2024 net product revenue ~$78M; ophthalmology implants (Iluvien, Yutiq) added ~35% of revenue by Q4 2025; pediatric\/primary-care (Karbinal ER, multivitamins) ~18% (~$6.5M YTD of $36M); pipeline AR101 (orphan) targets rare-disease upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 Revenue mix\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD ODT\/LiquiXR\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003ctd\u003eFY2024 net product revenue ~$78M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOphthalmology (Iluvien\/Yutiq)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003ctd\u003eAnalysts assign 30–40% enterprise value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric\/Primary Care\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003ctd\u003e~$6.5M YTD of $36M; gross margin ~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline (AR101)\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eOrphan designation; late-stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Aytu's Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Aytu’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing levers, promotion tactics, and placement opportunities to speed decision-making and align teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Wholesaler Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu uses national wholesalers AmerisourceBergen, Cardinal Health, and McKesson to supply over 10,000 retail pharmacies and 1,200 hospitals, ensuring broad US coverage.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Aytu reduced stockout rates to under 2% and cut average inventory days to ~18, improving fill times so prescriptions reach patients within 24–48 hours after a script.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Ophthalmology Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Alimera Sciences integration shifted Aytu toward specialized ophthalmology channels for retina products; Iluvien and similar implants now move through specialty distributors and direct-to-clinic models rather than retail scripts. This keeps high-cost implants (~$8,000–$10,000 per implant) handled with cold-chain and surgical logistics, reducing damage and delays. By late 2025, these channels account for an estimated 60% of retina-product shipments, underpinning Aytu’s distribution strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Physician Detailing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu deploys a focused sales force targeting high-prescribing pediatric, psychiatric, and ophthalmic physicians, concentrated in territories with the largest eligible patient pools; reps call on roughly 2,300 top prescribers nationwide. By late 2025 the team is cross-trained post-Alimera integration to sell the expanded portfolio, lifting reach by ~18% versus 2023. Face-to-face detailing remains the primary channel for placing products with key medical decision-makers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTelehealth and Digital Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAytu expanded on telehealth platforms to ease access to ADHD and pediatric meds, enabling remote consults and e-prescriptions filled by partner pharmacies.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 this digital placement captured a younger, tech-savvy cohort, cutting visit friction and boosting prescription volume—Aytu reported a telehealth-driven Rx increase of ~18% YoY in FY2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTelehealth e-Rx fills via partners\u003c\/li\u003e\n\u003cli\u003e18% telehealth-driven Rx growth FY2025\u003c\/li\u003e\n\u003cli\u003eTargets younger, digital-native patients\u003c\/li\u003e\n\u003cli\u003eReduces office-visit friction, raises adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThrough legacy Alimera operations, Aytu keeps a presence in parts of Europe and the Middle East, accessing patient pools across roughly 10 countries and regulatory regimes as of 2025.\u003c\/p\u003e\n\u003cp\u003eThis footprint lets Aytu test markets with different reimbursement rules and diversify revenue; international sales represented about 12% of combined legacy product revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Aytu aims to expand distribution via partnerships and licensing, targeting a 25–40% lift in international product reach to reduce US-market concentration risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePresent in ~10 countries (Europe, Middle East)\u003c\/li\u003e\n\u003cli\u003eInternational ≈12% of legacy product revenue in 2024\u003c\/li\u003e\n\u003cli\u003eGoal: 25–40% increase in international reach by end-2025\u003c\/li\u003e\n\u003cli\u003eMitigates US-only revenue concentration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-channel reach: 10k+ pharmacies, 60% retina share, telehealth +18% Rx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu’s Place mixes national wholesalers (AmerisourceBergen, Cardinal, McKesson) to reach 10,000+ pharmacies and 1,200 hospitals; specialty retina channels handle ~60% of implants; telehealth drove ~18% Rx growth in FY2025; international ~10 countries, ~12% revenue (2024). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e10,000+ pharmacies; 1,200 hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty\u003c\/td\u003e\n\u003ctd\u003e60% retina shipments; $8–10k\/unit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth\u003c\/td\u003e\n\u003ctd\u003e+18% Rx FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl\u003c\/td\u003e\n\u003ctd\u003e~10 countries; 12% rev 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eAytu 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Aytu 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750910603641,"sku":"aytubio-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/aytubio-marketing-mix.png?v=1772226741","url":"https:\/\/matrixbcg.com\/products\/aytubio-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}